Highlights

  • Cizzle Biotechnology raises GBP 250,000 through additional convertible loan notes from existing investor.
  • Funds will support commercialisation of the CIZ1B biomarker test in the UK, Europe, and North America.
  • Warrants issued cover 12.5 million ordinary shares with a 2p exercise price over two years.

Cizzle Biotechnology Holdings plc (LSE:CIZ) the UK-based diagnostics company developing early cancer detection tests, announced the issuance of additional unsecured convertible loan notes totaling up to GBP 250,000. The notes were issued to Frazer Lang, an existing shareholder in the company.

The new loan notes extend the original convertible loan notes of GBP 150,000 issued in May 2025 to Frazer Lang. The funds are intended to support the rollout and commercialisation of the CIZ1B biomarker test, which is designed to detect lung cancer at an early stage.

Terms of the Additional Notes

The Additional Notes will be issued in monthly tranches of GBP 50,000 and are convertible into ordinary shares of 0.01p each at 1.4p per share at the discretion of the note holder until 31 March 2026. No interest or fees are attached to the notes. The note holder has agreed to redeem both the original and additional notes through conversion into ordinary shares rather than seeking cash repayment.

Warrants Issued to Investor

In addition to the loan notes, Cizzle has issued warrants to Frazer Lang over 12,500,000 ordinary shares, exercisable at 2p per share within two years.

Commercial Expansion and Collaborations

Cizzle has entered a Letter of Intent with a medical diagnostic services provider working in partnership with the NHS. This agreement is part of the company’s initiative to make the CIZ1B test available in the UK and Europe.

The company is also continuing its collaboration with its US partner, Cizzle BIO Inc., to secure CLIA accreditation for the test and to complete a clinical evaluation study at Moffitt Cancer Center involving patients with suspicious lung nodules.

Funding and Operational Notes

The company does not plan to incur additional debt or adjust its share capital while the additional loan notes remain outstanding, except in the ordinary course of business. The proceeds from the notes will be applied to the company’s commercialisation activities in the UK, North America, and other markets.

Share performance of CIZ

CIZ’s shares traded at GBX 1.76 per share on 05 November 2025, up by 6.67% from its previous close of GBX 6.65.